Dott. Sergio Del Bianco

Medical Oncology

Nationality

Italienisch

Date of birth

29/10/1955

Languages

Italian, English

Websites and Social

Sergio Del Bianco

ll Dott. Sergio Del Bianco è specializzato in Oncologia Medica.

Si occupa principalmente del trattamento di neoplasie quali tumori del seno, del polmone, dell’intestino e della prostata. Vanta, inoltre, grande esperienza in immunoterapia e nell’esecuzione di test genetici.

Esperto di Targeted Therapy, effettua test genetici e biomolecolari in grado di stabilire quale sia il miglior farmaco più adatto al trattamento del tumore del singolo paziente. A questo scopo, è tra i pochi medici ad utilizzare la biopsia liquida.

Tra i primi ad utilizzare gli anticorpi monoclonali, è anche autore di un brevetto sull’impiego dell’Interferone nel trattamento medico del tumore mammario.
Attualmente svolge la sua attività come Libero Professionista presso la casa di cura Sanatrix a Roma.

Doctorates and Specializations

EDUCATION AND TRAINING

1983 – 1987: Fellowship in Oncology, National Cancer Institute, Milan;

1980 – 1983: Internship in Internal Medicine, Fatebenefratelli Hospital, Milan;

CLINICAL AND RESEARCH WORKING

Jan. 2020 – Now: Director, “Precision Oncology Dept.” – “Sanatrix” Hospital, Rome

May 2015 – Dic. 2019: Private Office, “Villa Mafalda Hosp.”, Rome

2003 – April 2015: Director, Medical Oncology Dept. “Madonna della Fiducia Hosp.”, Rome

1994 – 2003: Director, Medical Oncology Dept. “Villa Mafalda Hosp.”, Rome

1990 – 1994: Assistant, National Cancer Institute, Rome;

1987 – 1990: Clinical Investigator – Oncology Dept, C. Serono Reaserch Inst. – Rome

ACADEMIC APPOINTMENTS

From 1980: is member of A.I.O.M. (Italian Association of Medical Oncology).

From 1981 to 1983: is in the “Board of Directors” of A.I.O.M.

From 1985 to 1990: is in the “Board of Directors of S.I.E.I.O. (Italian Society of Endocrinology and Immulogy in Oncology).

From 1990: is “honorary member” of S.I.E.I.O.

From 1999: is member of A.S.C.O. (American Society of Clinical Oncology).

From 2000: is member of E.S.M.O. (European Society for Medical Oncology)

From 2003: is in the “Board of Directors”of A.M.O.S. (Medical Association for Management and Organization in Health
System.

From 1998: is Consultant of “Salem Oncology Centre” – Houston – Texas (U.S.A.)

Congresses and Conferences

Dose-intensity study with Epirubicin-Ciclophosfamide plus G-CSF in Advanced and Locally Advanced Breast Cancer. 30th A.S.C.O. – Meeting, Tucson–U.S.A., 1994.

Carboplatin (CBDCA), Etoposide (VP-16), and Vincristine (VCR), as first line therapy in Small Cell Lung Cancer (SCLC): a phase II trial. 15th E.S.M.O.–Congress, Dic. 2-5, Copenaghen – Danimarca, 1990

Surgery plus Thymostimulin vs. Surgery alone for removable large bowel carcinoma. 18th U.I.C.C.- Congress, Seattle-U.S.A., Sept. 1982.

Publications

Phase II intensified Epirubicin+Cyclofosfamide in Advanced Breast Cancer. Eur. J. Cancer, 30 a: 1285-1288, 1994.

Effect of natural-beta-interferon on cell proliferation and steroid receptor level in human breast cancer cells. Cancer, 60: 2419-2423, 1987.

Treatment of leukopenia induced by adjuvant chemotherapy: effect of lithium carbonate. Chemotherapy I/82, 26-29, 1982.